HCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HUTCHMED (China) Ltd is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show a bearish trend, and there is no significant positive momentum in the options market or trading signals. While the company has shown strong net income growth recently, the revenue decline and lack of clear bullish catalysts make it prudent to hold off on buying for now.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 32.859, and the moving averages indicate a bearish pattern (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 14.318, with key support at 13.443 and resistance at 15.192.
The company reported a significant increase in net income for 2025 ($457 million vs. $37.7 million in 2024), driven by core operations and asset disposals. Additionally, the initiation of a Phase I/IIa clinical trial for HMPL-A580 demonstrates progress in its R&D pipeline.
Revenue declined by 13% year-over-year to $548.51 million in 2025, reflecting market challenges. The MACD and moving averages indicate a bearish trend, and there are no recent significant insider or hedge fund trading activities. The options market shows low trading volume, and the implied volatility is high, suggesting uncertainty.
HUTCHMED reported a GAAP EPS of $2.62 for FY 2023 and a net income of $457 million for 2025, a significant improvement from $37.7 million in 2024. However, revenue declined by 13% year-over-year to $548.51 million, indicating market challenges.
BofA recently lowered the price target from $25 to $22 but maintained a Buy rating, citing positive data catalysts and improving access to capital in the biotech sector. However, concerns remain about the sustainability of these improvements.
